Established Prescription Drug Franchises

Own commercial drugmakers whose established prescription franchises fund research and pipeline renewal, rather than relying on speculative clinical breakthroughs. Merck, AbbVie and Amgen offer contrasting therapeutic exposures at forward earnings multiples of 9.1x, 16.2x and 15.6x, respectively. Approaching earnings provide a timely test of prescription demand and execution, while patent expirations, pricing pressure and trial setbacks remain key risks. Launch basket (equal weight): MRK, ABBV, AMGN, LLY, JNJ, GILD Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.